Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): An active and convenient regimen for advanced pancreatic cancer

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5211-5217

  Ardavanis, Alexandros ^a   Kountourakis, Panteleimon ^a   Karagiannis, Athanassios ^a   Doufexis, Dimitrios ^a   Tzovaras, Alexandros A ^a   Rigatos, Gerasimos ^a  

^a St Sawas Anticancer Hospital   (Greece)

Author keywords

Erlotinib; Gemcitabine; Overall survival; Pancreatic cancer; Toxicity

Indexed keywords

ERLOTINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; QUINAZOLINES; SURVIVAL RATE; TIME FACTORS;

EID: 75149144357     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
2. Mitry E, Rachet B, Quinn MJ, Cooper N and Coleman MP: Survival from cancer of the pancreas in England and Wales up to 2001. Br J Cancer 99: S21-23, 2008.
3. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C and Neoptolemos JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82: 111-115, 1995.
4. Rocha Lima CM and Centeno B: Update on pancreatic cancer. Curr Opin Oncol 14: 424-430, 2002.
5. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
6. Cohen SJ and Meropol NJ: Drug development in pancreatic cancer: finally, biology begets therapy. Int J Gastrointest Cancer 32: 91-106, 2002.
7. Heinemann V: Present and future treatment of pancreatic cancer. Semin Oncol 29: 3-31, 2002.
8. Jacobs JE and Megibow AJ: Cystic pancreatic neoplasms: CT appearances. Crit Rev Comput Tomogr 43: 361-381, 2002.
9. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM and Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530, 1996.
10. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002.
11. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, Lordick F, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A, Neugebauer S and Heinemann V: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19: 340-347, 2008.
12. Correale P, Messinese S, Marsili S, Ceciarini F, Pozzessere D, Petrioli R, Sabatino M, Cerretani D, Pellegrini M, Di Palma T, Neri A, Calvanese A, Pinto E, Giorgi G and Francini G: A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 89: 239-242, 2003.
13. Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP and O'Reilly EM: A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19: 86-91, 2008.
14. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A and Wilkowski R: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006.
15. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, and Lepere C and de Gramont A: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
16. Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B and Ducreux MP: Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 23: 9250-9256, 2005.
17. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22: 3776-3783, 2004.
18. Scheithauer W, Schull B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F and Kornek GV: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 14: 97-104, 2003.
19. Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK and Stathopoulos JG: Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 15: 1201-1204, 2006.
20. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y and Von Hoff D: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22: 1430-1438, 2004.
21. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM and Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552, 2007.
22. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
23. Ulrich-Pur H, Kornek GV, Raderer M, Haider K, Kwasny W, Depisch D, Greul R, Schneeweiss B, Krauss G, Funovics J and Scheithauer W: A phase II trial of biweekly high-dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 88: 2505-2511, 2000.
24. Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K and Kozuch P: Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Cancer Invest 21: 489-496, 2003.
25. Chang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J and Chen LT: Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterol Hepatol 21: 874-879, 2006.
26. Miksad RA, Schnipper L and Goldstein M: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25: 4506-4507, 2007.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-47 2009
28. Kloppel G, Lingenthal G, von Bulow M and Kern HF: Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 9: 841-856, 1985.
29. Trotti A, Colevas AD, Setser A, Rusch V, Jacques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3): 176-181, 2003
30. Kanzawa F and Saijo N: In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 24: 8-16, 1997.
31. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E and Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94: 902-910, 2002.
32. Miller VA and Kris MG: Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 27: 3-10, 2000.
33. Cascinu S, Silva RR, Barni S, Labianca R, Frontini L, Piazza E, Pancera G, Giordani P, Giuliodori L, Pessi MA, Fusco V, Luporini G, Cellerino R and Catalano G: A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 80: 1595-1598, 1999.
34. Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S and Cortes-Funes H: Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J ClinOncol 17: 585-592, 1999.
35. Oettle H and Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer 95: 912-922, 2002.
36. Igarashi H, Ito T, Kawabe K, Hisano T, Arita Y, Kaku T and Takayanaqi R: Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. World J Gastroenterol 14: 5311-5315, 2008.
37. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C and Fuchs CS: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25: 4787-4792, 2007.